Polymorphisms in the tissue factor pathway inhibitor gene are not associated with ischaemic stroke

Blood Coagulation and Fibrinolysis

Volumn 18, Issue 7, 2007, Pages 703-708

  Sayer, Milly S ^a   Cole, Vanessa J ^a   Adams, Murray J ^b   Baker, Ross I ^a   Staton, Janelle M ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Genotype; Polymorphism; Stroke; Tissue factor pathway; Tissue factor pathway inhibitor

Indexed keywords

TISSUE FACTOR PATHWAY INHIBITOR;

AGED; ARTICLE; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; CONTROL GROUP; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; STROKE PATIENT; UPREGULATION;

AGED; AMINO ACID SUBSTITUTION; AUSTRALIA; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LIPOPROTEINS; MALE; MATCHED-PAIR ANALYSIS; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; STROKE;

EID: 34748827976     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3282dde994     Document Type: Article

References (20)

1. McVey JH. Tissue factor pathway. Baillieres Best Pract Res Clin Haematol 1999; 12:361-372.
2. Dahm A, van HV, Bendz B, Rosendaal F, Bertina RM, Sandset PM. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003; 101:4387-4392.
3. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50:803-813.
4. Lindahl AK, Abildgaard U, Stokke G. Release of extrinsic pathway inhibitor after heparin injection: increased response in cancer patients. Thromb Res 1990; 59:651-656.
5. Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ Jr. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991; 78:387-393.
6. Lindahl AK, Jacobsen PB, Sandset PM, Abildgaard U. Tissue factor pathway inhibitor with high anticoagulant activity is increased in postheparin plasma and in plasma from cancer patients. Blood Coagul Fibrinolysis 1991; 2:713-721.
7. Nordfang O, Bjorn SE, Valentin S, Nielsen LS, Wildgoose P, Beck TC, Hedner U. The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity. Biochemistry 1991; 30:10371-10376.
8. Adams MJ, Thom J, Hankey GJ, Baker RI, Gilmore G, Staton J, Eikelboom JW. The tissue factor pathway in ischaemic stroke. Blood Coagul Fibrinolysis 2006; 17:527-532.
9. Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze GJ Jr. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1989; 338:518-520.
10. Amini-Nekoo A, Futers TS, Moia M, Mannucci PM, Grant PJ, Ariens RA. Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis. Br J Haematol 2001; 113:537-543.
11. Ameziane N, Seguin C, Borgel D, Fumeron F, Moatti D, Alhenc-Gelas M, et al. The -33T→C polymorphism in intron 7 of the TFPI gene influences the risk of venous thromboembolism, independently of the factor V Leiden and prothrombin mutations. Thromb Haemost 2002; 88:195-199.
12. Moatti D, Seknadji P, Galand C, Poirier O, Fumeron F, Desprez S, et al. Polymorphisms of the tissue factor pathway inhibitor (TFPI) gene in patients with acute coronary syndromes and in healthy subjects: impact of the V264M substitution on plasma levels of TFPI. Arterioscler Thromb Vasc Biol 1999; 19:862-869.
13. Kleesiek K, Schmidt M, Gotting C, Brinkmann T, Prohaska W. A first mutation in the human tissue factor pathway inhibitor gene encoding [P151L]TFPI. Blood 1998; 92:3976-3977.
14. Mues GI, Sarode R. Allele frequencies of tissue factor pathway inhibitor polymorphisms in African-American, Hispanic and Caucasian populations. Thromb Haemost 2002; 88:875-877.
15. Wang L, Hirayasu K, Ishizawa M, Kobayashi Y. Purification of genomic DNA from human whole blood by isopropanol-fractionation with concentrated Nal and SDS. Nucleic Acids Res 1994; 22:1774-1775.
16. Moatti D, Haidar B, Fumeron F, Gauci L, Boudvillain O, Seknadji P, et al. A new T-287C polymorphism in the 5′ regulatory region of the tissue factor pathway inhibitor gene. Association study of the T-287C and C-399T polymorphisms with coronary artery disease and plasma TFPI levels. Thromb Haemost 2000; 84:244-249.
17. Miyata T, Sakata T, Kumeda K, Uchida K, Tsushima M, Fujimura H, et al. C-399T polymorphism in the promoter region of human tissue factor pathway inhibitor (TFPI) gene does not change the plasma TFPI antigen level and does not cause venous thrombosis. Thromb Haemost 1998; 80:345-346.
18. Moatti D, Meirhaeghe A, Ollivier V, Bauters C, Amouyel P, de Prost D. Polymorphisms of the tissue factor pathway inhibitor gene and the risk of restenosis after coronary angioplasty. Blood Coagul Fibrinolysis 2001; 12:317-323.
19. Arnaud E, Moatti D, Emmerich J, Aiach M, de Prost D. No link between the TFPI V264M mutation and venous thromboembolic disease. Thromb Haemost 1999; 82:159-160.
20. Novo G, Caplice N, Tantillo R, Bonura F, Simari R, Novo S. TFPI antigen and activity levels in patients with asymptomatic atherosclerosis and target organ acute and chronic complications. Int Angiol 2005; 24:366-371.